Artificial Intelligence to automate the interpretation of pulmonary function tests to accurately and timely support diagnosis, treatment, and follow-up of lung diseases.
ArtiQ is a young, dynamic, and innovative spin-off company of the University of Leuven (Belgium). The company is founded in early 2019 by four committed founders with a long history in respiratory medicine, medical devices, and artificial intelligence. Working on a junction of multidisciplinary fields, founders identified opportunity and value that novel technologies could bring to all parties in a respiratory setting: patients, doctors, the healthcare systems, and industry. ArtiQ aims to become the trusted partner of medical practitioners for the diagnosis, treatment, and follow-up of respiratory problems. With the first developed artificial intelligence-based medical software, ArtiQ is already helping the interpretation of pulmonary function tests and improving lung disease diagnostic environment.
Total Funding: $1,125,980
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2019
